Skip to main
ABSI
ABSI logo

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci Corp demonstrates a promising outlook due to its strong clinical activity signals for ABS-101, which may enhance the probability of success in treating ulcerative colitis (UC) and Crohn's disease (CD) to 15%. The company has produced encouraging preclinical evidence for ABS-201, showcasing its efficacy in promoting hair growth and higher receptor occupancy compared to competing programs, potentially attracting interest from major pharmaceutical companies for partnerships. Furthermore, Absci's commitment to sign at least one deal with a large pharma partner by 2025, along with the expansion of its collaboration with Almirall for additional targets, underlines the company's growth potential in the biologics market.

Bears say

The financial outlook for Absci Corp appears negative primarily due to increased dilution resulting from a recent financing round, which has prompted a reduction in the stock's target price. Furthermore, significant challenges exist in the standard of care for non-hormonal treatment options in the endo market, which may hinder the company's growth potential. This situation is compounded by the high treatment burden on patients, leading to low retention and a preference for more permanent solutions, which could adversely affect Absci's marketable opportunities.

Absci Corp (ABSI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.